Tesaro Inc. (NASDAQ:TSRO)’s share price fell 1.7% on Wednesday . The company traded as low as $93.67 and last traded at $94.02, with a volume of 225,404 shares. The stock had previously closed at $95.60.

A number of brokerages recently weighed in on TSRO. Jefferies Group set a $80.00 price target on shares of Tesaro and gave the stock a “hold” rating in a report on Friday. Wedbush reissued a “buy” rating on shares of Tesaro in a report on Friday. Mizuho cut their price target on shares of Tesaro from $100.00 to $94.00 and set a “buy” rating on the stock in a report on Friday. Robert W. Baird began coverage on shares of Tesaro in a report on Monday, July 18th. They issued an “outperform” rating and a $105.00 price target on the stock. Finally, Wells Fargo & Co. reissued an “outperform” rating on shares of Tesaro in a report on Thursday, June 30th. Two analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $76.92.

The company’s market cap is $4.33 billion. The firm’s 50 day moving average is $77.10 and its 200 day moving average is $50.75.

Tesaro (NASDAQ:TSRO) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.28) EPS for the quarter, topping the consensus estimate of ($1.71) by $0.43. The business had revenue of $36.60 million for the quarter, compared to analyst estimates of $4.98 million. During the same quarter in the prior year, the business earned ($1.51) earnings per share. On average, equities analysts predict that Tesaro Inc. will post ($7.16) EPS for the current year.

In related news, VP Jeffrey H. Hanke sold 12,500 shares of Tesaro stock in a transaction that occurred on Thursday, June 30th. The shares were sold at an average price of $74.35, for a total transaction of $929,375.00. Following the sale, the vice president now directly owns 12,500 shares in the company, valued at approximately $929,375. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Edward C. English sold 7,000 shares of Tesaro stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $40.75, for a total transaction of $285,250.00. Following the sale, the vice president now owns 3,500 shares in the company, valued at $142,625. The disclosure for this sale can be found here.

A number of large investors have bought and sold shares of TSRO. Rhumbline Advisers increased its stake in Tesaro by 9.3% in the fourth quarter. Rhumbline Advisers now owns 22,403 shares of the biopharmaceutical company’s stock valued at $1,172,000 after buying an additional 1,915 shares in the last quarter. Bank of Montreal Can increased its position in shares of Tesaro by 9,925.5% in the fourth quarter. Bank of Montreal Can now owns 24,362 shares of the biopharmaceutical company’s stock worth $1,275,000 after buying an additional 24,119 shares during the period. Nationwide Fund Advisors increased its position in shares of Tesaro by 1.3% in the fourth quarter. Nationwide Fund Advisors now owns 26,647 shares of the biopharmaceutical company’s stock worth $1,394,000 after buying an additional 330 shares during the period. Mutual of America Capital Management LLC increased its position in shares of Tesaro by 95.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 39,520 shares of the biopharmaceutical company’s stock worth $2,068,000 after buying an additional 19,320 shares during the period. Finally, Jennison Associates LLC increased its position in shares of Tesaro by 157.5% in the fourth quarter. Jennison Associates LLC now owns 938,461 shares of the biopharmaceutical company’s stock worth $49,100,000 after buying an additional 574,041 shares during the period.

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.